RAJYALAKSHMI LUTHRA to Molecular Targeted Therapy
This is a "connection" page, showing publications RAJYALAKSHMI LUTHRA has written about Molecular Targeted Therapy.
Connection Strength
0.181
-
Molecular Profile of Advanced Thyroid Carcinomas by Next-Generation Sequencing: Characterizing Tumors Beyond Diagnosis for Targeted Therapy. Mol Cancer Ther. 2018 07; 17(7):1575-1584.
Score: 0.077
-
A pathway-based gene signature correlates with therapeutic response in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Mod Pathol. 2010 Nov; 23(11):1524-34.
Score: 0.045
-
Diagnostic, Prognostic, and Predictive Utility of Recurrent Somatic Mutations in Myeloid Neoplasms. Clin Lymphoma Myeloma Leuk. 2017 07; 17S:S62-S74.
Score: 0.018
-
Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic. Clin Cancer Res. 2014 Dec 15; 20(24):6336-45.
Score: 0.015
-
PIK3CA mutations in advanced cancers: characteristics and outcomes. Oncotarget. 2012 Dec; 3(12):1566-75.
Score: 0.013
-
Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res. 2012 Nov 15; 18(22):6373-83.
Score: 0.013